DE69803750T2 - Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften - Google Patents

Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften

Info

Publication number
DE69803750T2
DE69803750T2 DE69803750T DE69803750T DE69803750T2 DE 69803750 T2 DE69803750 T2 DE 69803750T2 DE 69803750 T DE69803750 T DE 69803750T DE 69803750 T DE69803750 T DE 69803750T DE 69803750 T2 DE69803750 T2 DE 69803750T2
Authority
DE
Germany
Prior art keywords
compound
group
formula
salts
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69803750T
Other languages
German (de)
English (en)
Other versions
DE69803750D1 (de
Inventor
Ranjan Chakrabarti
Madhavan Gurram
Bhushan Lohray
Rajagopalan Ramanujam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REDDY S RES FOUNDATION ANDHRA
Dr Reddys Research Foundation
Reddy Cheminor Inc
Original Assignee
REDDY S RES FOUNDATION ANDHRA
Dr Reddys Research Foundation
Reddy Cheminor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/982,962 external-priority patent/US6011036A/en
Application filed by REDDY S RES FOUNDATION ANDHRA, Dr Reddys Research Foundation, Reddy Cheminor Inc filed Critical REDDY S RES FOUNDATION ANDHRA
Publication of DE69803750D1 publication Critical patent/DE69803750D1/de
Application granted granted Critical
Publication of DE69803750T2 publication Critical patent/DE69803750T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69803750T 1997-12-02 1998-04-10 Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften Expired - Fee Related DE69803750T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/982,962 US6011036A (en) 1997-04-15 1997-12-02 Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
PCT/US1998/007285 WO1998045292A1 (en) 1997-12-02 1998-04-10 Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties

Publications (2)

Publication Number Publication Date
DE69803750D1 DE69803750D1 (de) 2002-03-21
DE69803750T2 true DE69803750T2 (de) 2002-09-12

Family

ID=25529696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69803750T Expired - Fee Related DE69803750T2 (de) 1997-12-02 1998-04-10 Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften

Country Status (6)

Country Link
EP (1) EP0971917B1 (OSRAM)
JP (1) JP4391597B2 (OSRAM)
AT (1) ATE212991T1 (OSRAM)
AU (1) AU6966498A (OSRAM)
DE (1) DE69803750T2 (OSRAM)
WO (1) WO1998045292A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
DE60114996T2 (de) 2000-03-08 2006-08-10 Novo Nordisk A/S Senkung des serum cholesterols
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
US7196085B2 (en) * 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
MXPA06003474A (es) 2003-09-30 2006-06-05 Novo Nordisk As Agonistas de receptores de melanocortina.
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
JP2007536344A (ja) 2004-05-04 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ 新規のインドール誘導体
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US8148412B2 (en) 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
DK1951658T3 (da) 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
US8394842B2 (en) 2006-03-28 2013-03-12 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
EP2552950A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
MY167234A (en) 2011-09-23 2018-08-14 Novo Nordisk As Novel glucagon analogues
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
JP2020514365A (ja) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
EP0971917B1 (en) 2002-02-06
EP0971917A1 (en) 2000-01-19
JP2002508745A (ja) 2002-03-19
DE69803750D1 (de) 2002-03-21
WO1998045292A1 (en) 1998-10-15
JP4391597B2 (ja) 2009-12-24
AU6966498A (en) 1998-10-30
ATE212991T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
DE69727837T2 (de) Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
DE69723869T2 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
EP0971917B1 (en) Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
US6310069B1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6313113B1 (en) Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
EP0923580A1 (en) Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US4074048A (en) Process for the preparation of 4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides
CH624395A5 (OSRAM)
US5889025A (en) Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6159966A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
DD201790A5 (de) Verfahren zur herstellung von 3-aryl-5-isothiazolen
DE69123315T2 (de) 6,7-Dihydro-3-Phenyl-1,2-benzisoxazol-4(5H)-one und -ole, ein Verfahren für ihre Herstellung und ihre Verwendung als Arzneimittel
US5801173A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
EP0116708A1 (de) Neue substituierte 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69824756T2 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
DE69625795T2 (de) Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
US5889032A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US4018762A (en) Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide
WO1998052946A1 (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension
DD254001A5 (de) Verfahren zur herstellung von heterocyclischen oxophtalazinylessigsaeuren
DE69625856T2 (de) Substituiertes Benzothiazinderivat
US5919782A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6573268B1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE69716592T2 (de) Neue heterozyklische verbindungen mit antidiabetischen, hypolipiddaemischen und blutdrucksenkenden eigenschaften, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten
EP0346683A1 (de) Pyrrolderivate, ihre Herstellung und ihre Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee